Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pepinemab - Vaccinex

Drug Profile

Pepinemab - Vaccinex

Alternative Names: Anti-SEMA4D monoclonal antibody - Vaccinex; moAb VX15/2503; VX 15; VX 15/2503

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccinex
  • Developer Bristol-Myers Squibb; Children's Oncology Group; Emory University; Merck KGaA; National Cancer Institute (USA); Teva Pharmaceutical Industries; UCLAs Jonsson Comprehensive Cancer Center; Vaccinex
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I/II Non-small cell lung cancer; Osteosarcoma; Solid tumours
  • Phase I Colorectal cancer; Head and neck cancer; Malignant melanoma; Pancreatic cancer
  • No development reported Multiple sclerosis

Most Recent Events

  • 27 Sep 2019 Safety, efficacy and immunogenicity data from a phase Ib/II trial in Non-small cell lung cancer released by Vaccinex
  • 25 Sep 2019 Updated interim efficacy and immunogenicity data from the phase Ib/II CLASSICAL-Lung trial in Non-small cell lung cancer presented at the 5th International Cancer Immunotherapy Conference (CICON-2019)
  • 13 Aug 2019 Vaccinex completes enrolment in its phase Ib/II CLASSICAL-Lung trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03268057)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top